MURRAY HILL, N.J.--(BUSINESS WIRE)--June 23, 2003--C. R. Bard,
Inc. (NYSE-BCR) today announced the introduction of the Fluent(TM)
constant flow pump in Europe, for implantation in patients for the
treatment of chronic pain. The product will be marketed by Bard Access
Systems, Inc., its subsidiary located in Salt Lake City, Utah,
pursuant to a license and other arrangements with Infumedics Inc. of
East Walpole, Massachusetts.
Implanted infusion pumps are used to treat a variety of medical
conditions, most notably in the area of chronic pain management for
the continuous delivery of morphine to the spinal cord. Chronic pain
afflicts over 100 million people worldwide and is comprised of both
malignant and non-malignant disease patient populations.
Constant flow pumps are devices with a fixed flow rate and a life
generally estimated at 15 years. Novel features of the Fluent pump
include a polymer housing that reduces its size and weight and Bard's
superior catheter technology.
Dr. Paolo Poli, director of pain therapy and palliative care,
Santa Chiara Hospital, Pisa, Italy, and first in the world to place
the pump, comments, "The Fluent constant flow pump's advanced design
with the new, easy to use catheter lock connection, has streamlined
this surgical procedure saving me time in the O.R. Additionally, its
smooth ergonomic shape and light weight appeals to the needs of my
William H. Longfield, chairman and chief executive officer, said,
"The launch of the Fluent constant flow pump marks a significant
milestone in our strategy to enter the growing area of pain
management. We expect to follow this with the launch of a programmable
device in 2004. This market represents an excellent growth opportunity
for Bard and we are truly excited about our strategy to capitalize on
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
New Jersey, is a leading multinational developer, manufacturer and
marketer of health care products in the fields of vascular, urology,
oncology and surgical specialty products.
This press release contains forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Please refer to our March 31, 2003, Form 10-Q for a statement with
regard to forward-looking statements, including disclosure of
additional factors that could cause actual results to differ
materially from those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908/277-8413
Holly P. Glass, 703/754-2848
SOURCE: C. R. Bard, Inc.